Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Combination therapy with TS-1].

Masato Fujii1

  • 1Dept. of Otolaryngology, National Tokyo Medical Center, Higashigaoka, Tokyo, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|December 15, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comprehensive analysis of oncological outcomes of radical cystectomy for non-muscle invasive bladder cancer.

Scientific reports·2026
Same author

Staple-line-associated lung adenocarcinoma years after video-assisted thoracoscopic surgical bullectomy for pneumothorax.

Respiratory medicine case reports·2026
Same author

Serum interferon-λ3 as a short-term biomarker of disease control in anti-MDA5-positive dermatomyositis-associated ILD.

Scientific reports·2026
Same author

Age-stratified outcomes of radical cystectomy for muscle-invasive bladder cancer: a nationwide multicenter study of 1867 patients in Japan.

Japanese journal of clinical oncology·2026
Same author

Biological Aging and Survival Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Receiving Systemic Therapy.

Clinical lung cancer·2025
Same author

Long-acting muscarinic antagonist versus leukotriene receptor antagonist as additional treatment in uncontrolled asthma patients used inhaled corticosteroids and long-acting β2 adrenergic agonist: a randomized phase 2 screening trial.

Respiratory medicine and research·2025

TS-1, an oral chemotherapy, shows a 67.6% response rate for head and neck squamous cell carcinoma (HNSCC). This oral agent offers better patient compliance and comparable or reduced toxicity compared to 5-FU, making it a promising HNSCC treatment.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Cisplatin (CDDP) and 5-FU are standard chemotherapy for head and neck squamous cell carcinoma (HNSCC).
  • TS-1, an oral tegafur derivative, is an active agent for HNSCC.
  • Existing studies report on combinations of CDDP and TS-1 for HNSCC.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of TS-1-based regimens in HNSCC patients.
  • To assess the potential of TS-1 as an orally administered alternative to intravenous 5-FU.

Main Methods:

  • A clinical phase II study was conducted combining CDDP and TS-1.
  • Patient compliance and adverse effects, particularly bone marrow toxicity, were monitored.
  • Comparison with existing data for CDDP/5-FU and other TS-1 combinations.

Related Experiment Videos

Main Results:

  • The combination of CDDP and TS-1 demonstrated a 67.6% response rate in advanced and recurrent HNSCC.
  • TS-1 offers improved patient compliance due to oral administration.
  • Adverse effects, including bone marrow toxicity, were comparable or better than 5-FU injection.

Conclusions:

  • TS-1-containing regimens are effective for HNSCC treatment.
  • TS-1 combined with radiotherapy shows promise for outpatient management of advanced HNSCC.
  • Further large-scale, multi-institutional phase II studies are warranted to confirm efficacy and safety.